CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 256 enrolled
Drug / intervention
Tamoxifen +1 moredrug
Likely dose
Tamoxifen 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00999921
NCT00999921Phase 4Completed

A Single Blinded Randomized Controlled Trial of the Comparative Effects of Tamoxifen and Evening Primrose Oil in Premenopausal Non-high Risk Patients With Benign Breast Disease With Respect to the Estrogen Receptor Status.

Medical College and Hospital Kolkata·interventional·Posted Oct 22, 2009·Updated May 18, 2015

In Brief

A Phase 4 clinical trial evaluating Tamoxifen and Evening Primrose Oil for Benign Breast Disease and 3 related conditions. Completed, enrolled 256 participants across 1 site.

Detailed Summary

The purpose of the study is to determine the efficacy and relapse rate of low dose, short duration treatment with tamoxifen in benign breast disease amenable to hormonal therapy with respect to etiology and estrogen receptor status and to realize its side-effects and cost of therapy. To do a comparative analysis of the results with evening primrose oil which is one of the first line management in benign breast disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIndia
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 22, 2009
Enrollment StartJan 1, 2008
Primary CompletionAug 1, 2014
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 16.7 years ago

Interventions

Tamoxifendrug

Tamoxifen is given at 10 mg once daily between Day 5 and Day 25 of menstrual cycle for 3 cycles.

Evening Primrose Oildrug

Evening Primrose Oil is given at 1000 mg two times daily for 3 months.